We focus on key analyzes such as ctDNA, mutational profiling of actionable and resistance genes, soluble immune checkpoints (e.g., sPD-L1), peripheral blood immune cell ratios (e.g., NLR), and plasma-based tumor mutational burden (cTMB) (Figure 1). This evidence concerns the gene SPDL1 and neoplasm.